Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.50
Bid: 39.00
Ask: 40.00
Change: 0.50 (1.28%)
Spread: 1.00 (2.564%)
Open: 39.00
High: 39.50
Low: 39.00
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

30-year exclusive distribution deal signed

26 Jan 2015 07:00

RNS Number : 0861D
Venture Life Group PLC
26 January 2015
 



26 January 2015

 

Venture Life Group plc

 

("Venture Life" or "the Group")

 

30-year exclusive distribution deal with major skincare and cosmetics retailer in China

 

Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, announces that it has signed an exclusive 30-year distribution deal with one of the largest skincare and cosmetics retail chains in China.

 

The agreement is with REC Cosmetics (Shanghai) Limited ("REC"), a subsidiary of Gialen Group Co. Ltd ("Gialen"). Gialen is a privately owned business with 10,000 employees operating in over 1,000 of its own retail skincare and cosmetics stores across mainland China. Gialen is currently undertaking a rapid new store opening programme and over 300,000 customers currently visit their stores daily.

 

Under the terms of the distribution agreement, REC has the exclusive right to sell an initial range of 15 skincare products, including some products from Venture Life's anti-ageing range, ("the Initial Range") in China, Macau, Hong Kong and Taiwan. Venture Life will be the exclusive manufacturer and supplier to REC for all current and any future products under the agreement.

 

The Initial Range is expected to be launched in Gialen Group stores in China in the second half of 2015, subject to registration approval. For the Initial Range, contractual annual minimum purchase obligations ("MPO") have been agreed, the achievement of which maintains REC's rights to distribute the products. The MPO are worth approximately RMB 52.8m (£5.7m)* in sales for Venture Life over the first five years after product registration, including RMB 8.5m (£0.9m)* during the first year after registration. Over the full term of the agreement, the total MPO are worth approximately RMB 371m/£40m* in sales for Venture Life.

 

Jerry Randall, Chief Executive Officer of Venture Life, commented:

 

"We are delighted to have signed a very significant deal with such a progressive, fast-growing Chinese skincare and cosmetics business. We have worked through a very detailed process to arrive at this agreement with a partner who clearly shares our philosophy, ethos and ambition to grow in China.

 

"This agreement demonstrates there is a strong appetite for our products in China and the other territories, where the demand for high quality Western products, particularly in skincare, remains strong. Our Italian manufacturing capacity and capability has also been a major factor in securing this agreement, and further validates our strategic approach as an integrated product development, manufacturing and commercialisation company. We expect this deal to represent just the start of a very successful collaboration with Gialen in China."

 

* At current exchange rates as the Initial Range is priced in RMB.

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742 870

 

Panmure Gordon (UK) Limited Freddy Crossley / Duncan Monteith +44 (0) 20 7886 2500Corporate Finance

Tom SalvesenCorporate Broking

 

Square1 Consulting

David Bick

Mark Longson +44 (0) 20 7929 5599

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About Gialen

Gialen was founded in 2005 and is headquartered in Guangzhou, China. Gialen is one of the largest cosmetics retail chains in China with over 1,000 stores and 300,000 customers daily.

 

Gialen sells an extensive range of products, listing some of the world's best known skincare, cosmetics and personal-care brands including L'Oreal, Shiseido, Olay and Nivea.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBAMBTMBMTTAA
Date   Source Headline
17th May 20227:00 amRNSFinal Results
10th May 202211:31 amRNSExercise of Share Options & Voting Rights
19th Apr 20227:00 amRNSReporting Update
23rd Mar 20223:00 pmRNSAnnouncement re: Full year results
22nd Feb 20227:00 amRNSGrant of Options and PDMR Dealing
21st Feb 20227:00 amRNSResults - clinical trial led by Cardiff University
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:37 pmRNSPrice Monitoring Extension
31st Jan 20222:06 pmRNSSecond Price Monitoring Extn
31st Jan 20222:01 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTrading Statement
24th Jan 20222:06 pmRNSSecond Price Monitoring Extn
24th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSBusiness Update
29th Dec 202112:34 pmRNSDirector/PDMR Shareholding
20th Dec 20214:13 pmRNSDirectorate Change
14th Dec 202111:05 amRNSSecond Price Monitoring Extn
14th Dec 202111:01 amRNSPrice Monitoring Extension
3rd Dec 20214:22 pmRNSDirector/PDMR Shareholding
1st Dec 20219:06 amRNSSecond Price Monitoring Extn
1st Dec 20219:00 amRNSPrice Monitoring Extension
1st Dec 20217:00 amRNSTrading Update & Board Changes
1st Nov 20212:00 pmRNSPrice Monitoring Extension
1st Nov 20218:44 amRNSHolding(s) in Company
1st Nov 20218:43 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSHolding(s) in Company
11th Oct 20212:41 pmRNSHolding(s) in Company
23rd Sep 20219:05 amRNSSecond Price Monitoring Extn
23rd Sep 20219:00 amRNSPrice Monitoring Extension
23rd Sep 20217:00 amRNSHalf-year Report
7th Sep 20211:54 pmRNSHolding(s) in Company
13th Aug 20219:05 amRNSSecond Price Monitoring Extn
13th Aug 20219:00 amRNSPrice Monitoring Extension
13th Aug 20217:00 amRNSTrading Update and Progress on recent Acquisitions
6th Aug 20217:00 amRNSAcquisition of Oncology Support Product Assets
21st Jun 20217:00 amRNSRevolving Credit Facility
7th Jun 20217:00 amRNSAcquisition of BBI Healthcare Limited
20th May 20212:29 pmRNSResult of AGM
14th Apr 20214:19 pmRNSHolding(s) in Company
25th Mar 20212:19 pmRNSConfirmation of AGM Date
25th Mar 20217:00 amRNSFinal Results
25th Feb 20217:00 amRNSInvestor Presentation
1st Feb 20217:00 amRNSTrading Update & Notice of Results
14th Dec 20202:07 pmRNSIssue of Equity
11th Dec 20207:27 amRNSHolding(s) in Company
10th Dec 20204:45 pmRNSHolding(s) in Company
10th Dec 20204:41 pmRNSHolding(s) in Company
10th Dec 20202:42 pmRNSHolding(s) in Company
10th Dec 20201:45 pmRNSHolding(s) in Company
9th Dec 20202:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.